



**HAL**  
open science

## Randomized study of the effect of gadopiclesol, a new gadolinium-based contrast agent, on the QTc interval in healthy subjects

Christian Funck-Brentano, Mathieu Felices, Nathalie Le Fur, Corinne Dubourdieu, Pierre Desché, Frédéric Vanhoutte, Pascal Voiriot

### ► To cite this version:

Christian Funck-Brentano, Mathieu Felices, Nathalie Le Fur, Corinne Dubourdieu, Pierre Desché, et al.. Randomized study of the effect of gadopiclesol, a new gadolinium-based contrast agent, on the QTc interval in healthy subjects. *British Journal of Clinical Pharmacology*, In press, 10.1111/bcp.14309 . hal-02875281

**HAL Id: hal-02875281**

**<https://hal.sorbonne-universite.fr/hal-02875281>**

Submitted on 19 Jun 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# **Randomized study of the effect of gadopiclesol, a new gadolinium-based contrast agent, on the QTc interval in healthy subjects.**

Christian Funck-Brentano<sup>1</sup>, Mathieu Felices<sup>2</sup>, Nathalie Le Fur<sup>3</sup>, Corinne Dubourdieu<sup>3</sup>,  
Pierre Desché<sup>3</sup>, Frédéric Vanhoutte<sup>4</sup>, Pascal Voiriot<sup>5</sup>

<sup>1</sup> INSERM, CIC-1901 and UMRS 1166, F-75013 Paris, France; AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology and CIC-1901, F-75013 Paris, France; Sorbonne Université Médecine, F-75013 Paris, France; Institute of Cardiometabolism and Nutrition (ICAN), F-75013 Paris, France,

<sup>2</sup> Phinc, 36, rue Victor Basch, 91300 Massy, France

<sup>3</sup> Guerbet, BP57400, 95943 Roissy CDG Cedex, France

<sup>4</sup> SGS Clinical Pharmacology Unit, ZNA Stuivenberg, Antwerp, Belgium

<sup>5</sup> Cardiabase, 78 avenue du XXème Corps, 54000 Nancy, France,

**Corresponding author:** Christian Funck-Brentano, Service de Pharmacologie Médicale & CIC-1901, Hôpital Pitié-Salpêtrière, F-75013. E-mail: [christian.funck-brentano@aphp.fr](mailto:christian.funck-brentano@aphp.fr)

**PI statement:** The authors confirm that the Principal Investigator for this paper is Frédéric Vanhoutte and that he had direct clinical responsibility for the subjects.

**Running title:** Thorough QT study of gadopiclesol

**Keywords:** contrast media; electrocardiography; healthy volunteers;

**Word count:** 3709    **Table count:** 3    **Figure count:** 3

## **ABSTRACT**

### **AIM**

We investigated the effect of gadopiclesol, a new gadolinium-based contrast agent, on the QTc interval at clinical and supra-clinical dose, considering the relative hyperosmolarity of this product.

### **METHODS**

This was a single centre, randomized, double-blind, placebo- and positive-controlled, four-way crossover study. Forty-eight healthy male and female subjects were included to receive single intravenous (i.v.) administrations of gadopiclesol at the clinical dose of 0.1 mmol·kg<sup>-1</sup>, standard for current gadolinium-based contrast agents, the supra-clinical dose of 0.3 mmol·kg<sup>-1</sup>, placebo and a single oral dose of 400 mg moxifloxacin.

### **RESULTS**

The largest time-matched placebo-corrected, mean change from-baseline in QTcF ( $\Delta\Delta\text{QTcF}$ ) was observed 3 h after administration of 0.1 mmol·kg<sup>-1</sup> gadopiclesol (2.39 ms, 90% confidence interval (CI): 0.35, 4.43 ms) and 5 min after administration of 0.3 mmol·kg<sup>-1</sup> (4.81 ms, 90%CI: 2.84; 6.78 ms). The upper limit of the 90% CI was under the threshold of 10 ms, demonstrating no significant effect of gadopiclesol on QTc interval. From 1.5 to 4 h post-dose moxifloxacin, the lower limit of the 90% CI of  $\Delta\Delta\text{QTcF}$  exceeded 5 ms demonstrating assay sensitivity. Although there was a positive slope, the concentration-response analysis estimated that the values of  $\Delta\Delta\text{QTcF}$  at the maximal concentration of gadopiclesol at 0.1 and 0.3 mmol·kg<sup>-1</sup> were 0.41 and 2.23 ms, respectively, with the upper limit of the 90% CI not exceeding 10 ms. No serious or severe adverse events or treatment discontinuations due to adverse events were reported.

## CONCLUSION

This thorough QT/QTc study demonstrated that gadopiclesol did not prolong the QT interval at clinical and supra-clinical doses and was well tolerated in healthy volunteers. The positive slope of the QTc prolongation vs. concentration relationship suggests that hyperosmolarity could be associated with QTc prolongation. However, the amplitude of this effects is unlikely to be associated with proarrhythmia.

**Key words:** Gadopiclesol, Thorough QT study, QTc interval, Osmolarity, healthy subjects.

## WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT

- Gadopiclesol is a gadolinium-based contrast agent in clinical development.
- Hyperosmolarity is associated with a reduction of [hERG](#) (KCNH2) current and only one thorough QT study has been reported with gadolinium-based contrast agents.

## WHAT THIS STUDY ADDS

- This study demonstrated that intravenous administration of gadopiclesol at clinical and supra-clinical doses does not prolong the QTc interval. There was no difference in the occurrence of adverse events or other safety parameters between gadopiclesol and placebo, supporting the overall good safety profile of gadopiclesol.
- The study supports the view that hyperosmolarity of gadolinium-based contrast agent is not associated with clinically significant prolongation of ventricular repolarization.
- However, since there was a positive relationship between QTc prolongation and gadopiclesol concentration, it cannot be excluded that contrast agents of greater osmolarity could be associated with clinically significant QTc prolongation.

## Introduction

Magnetic resonance imaging (MRI) is a widely used technique in the diagnosis of a large number of pathologies but most notably in the field of oncology. It has allowed more accurate tumour detection, characterization and staging [1]. Often contrast agents are used to improve the MRI imaging [1, 2]. These agents most typically contain the paramagnetic gadolinium ion in a chelated form to avoid its potential toxicity. Two types of chelates, linear and macrocyclic, have been approved by regulatory authorities. Linear chelates are less stable than macrocyclic chelates, and thus more prone to release gadolinium within the body.

The pharmacokinetics of the marketed gadolinium-based contrast agents (GBCAs), which are administered intravenously (i.v.), is very similar in that they distribute only in the extracellular space, are excreted via the kidneys and have a half-life of 1 to 2 h [3, 4]. In patients with severe renal impairment, administration of GBCAs, mainly if not exclusively the linear chelates, has been associated with the development of nephrogenic systemic fibrosis most likely due to accumulation of dissociated gadolinium in tissues [5, 6]. In recent years, it has become increasingly clear that with linear GBCAs, gadolinium deposits can also be found in bone and other tissues including brain in patients with normal kidney function and an intact blood brain barrier exposed to multiple cumulative doses. Although clinical data on the potential toxicity of these gadolinium deposits is sparse [7-10], linear GBCAs have been suspended in Europe (except from gadobenic acid and gadoxetate disodium restricted to liver MRI) while macrocyclic GBCAs are still fully authorized due to their favourable benefit risk balance. Therefore, safety of new GBCAs must be ascertained.

Gadopipiclenol is a new macrocyclic GBCA in clinical development. As part of the development of a compound, cardiac safety needs to be assessed in preclinical models and clinical studies. Gadopipiclenol induced a concentration-dependent inhibition of [hERG](#) tail current amplitude (data on file) but this effect was considered to be non-specific and due to

the hyperosmolarity of the tested solutions and to the relatively high molecular weight (970.1 g/mol) of gadopiclesol. Hyperosmolarity has been shown to inhibit hERG current [11] and to transiently increase dispersion of refractoriness following intracoronary infusions of contrast agents [12]. Gadopiclesol had no effect on the action potential of rabbit Purkinje fibres nor did it prolong the QTc interval *in vivo* in conscious dogs (Guerbet, data on file). Further, no cardiac events were reported in the first-in man study [13] and in a dose-response phase IIb study [14].

In the present study, the QT/QTc interval prolongation of gadopiclesol was investigated in a dedicated thorough QTc study which was performed according to the ICH E14 guideline [15].

## **Methods**

The study was performed in compliance with the principles of the Declaration of Helsinki and Good Clinical Practice. The study was registered with ClinicalTrials.gov (ref: NCT03657264). The protocol, its amendments, and any other written information provided to subjects were approved by an independent Ethics Committee (ZNA/OCMW Antwerp, Belgium). The study was performed in a single centre (SGS Clinical Pharmacology Unit, Antwerp, Belgium) and only started after approval of the competent national health authority was received. Written informed consent was obtained from all subjects prior to any study-related assessment took place.

### *Subjects*

Eligibility of the 48 subjects who participated in the study was assessed at the screening visit, which took place within 4 weeks prior to first study treatment administration. Subjects were included if they were healthy, male or female between 18 and 60 years of age, with a body mass index between 19 and 28 kg/m<sup>2</sup> and weighing at least 40 (females) or 50 (males) kg and

no more than 100 kg. Subjects could not participate in case of a history or family history of inherited or acquired Long QT syndrome or risk factors for Torsade de Pointe, unexplained loss of consciousness or convulsion or any history of clinically significant bradycardia, cardiac impairment due to decreasing left ventricular ejection fraction, or arrhythmia (including Wolf-Parkinson-White syndrome). Non-cardiac exclusion criteria included smoking more than 10 cigarettes per day, any history of severe allergy or allergic disease, treatment with any concomitant medications which could induce QT prolongation and administration of any contrast agent within 2 weeks before inclusion or scheduled to receive any contrast agent within 3 months after the last investigational medicinal product administration.

### *Study design*

This single-centre study was conducted according to a randomised, 4-way crossover, double-blind placebo-controlled and open-label positive-controlled (moxifloxacin) design. Each subject was randomised to one of 4 sequences of the 4 study treatments according to a Williams's design [16] which was balanced for first order carry-over effect. The 4 study treatments were: bolus i.v. placebo (0.9% NaCl), bolus i.v. gadopichlenol at the dose of  $0.1 \text{ mmol}\cdot\text{kg}^{-1}$ , standard dose for most currently approved GBCAs, bolus i.v. gadopichlenol at the supra-clinical dose of  $0.3 \text{ mmol}\cdot\text{kg}^{-1}$  and oral 400 mg moxifloxacin. The supra-clinical dose was set at  $0.3 \text{ mmol}\cdot\text{kg}^{-1}$ , which is a dose still used for some approved GBCAs for limited applications. Starting at time zero, gadopichlenol was administered at a rate of 2 mL/s with a total volume of 11 to 58 mL, i.e. in 5.5 to 29 seconds, depending on volunteer's body weight and gadopichlenol dose administered.

Each treatment period lasted 72 h resulting in a total study duration of 12 days for each participant during which the subjects remained confined in the clinical trial unit. One and

3 months after last study drug administration, subjects had to return to the clinical trial unit to assess the long-term elimination of gadopiclesol.

### *ECG recordings*

During each treatment period, 12-lead Holter ECG monitoring using a Mortara H12+<sup>®</sup> (Milwaukee, WI, USA) was performed from 1 h before each administration (baseline) and up to 24 h post-administration. Triplicate ECGs were extracted from the recordings using a dedicated software (Antares<sup>®</sup>, AMPS, Montichiari, Italy) at the following time points for gadopiclesol and placebo: predose and then 5 min, 10 min, 20 min, 30 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 8 h, and 24 h postdose. For moxifloxacin, the time points were: predose and then 30 min, 1 h, 1.5 h, 2 h, 3 h, 4 h postdose.

Using a computerized measurement system, calipers were placed on the recording based upon the global waveforms from all 12-leads. A qualified cardiologist not otherwise involved in the study and blinded to treatment then adjudicated the placement of the calipers on the ECG tracing and performed adjustments if warranted. He/she also noted any significant morphological abnormality on the tracing. All tracing from a given subjects were measured by the same observer.

QT values were corrected for heart rate using Fridericia's and Bazett's formulae and plots were created of QTc versus RR intervals of baseline and placebo data. The correction according to Fridericia showed a horizontal regression line for the relationship between QTc and RR whereas that for Bazett's correction (QTcB) deviated significantly from horizontal. This indicated that the Fridericia formulae was the appropriate correction for QT in the current study.



### *Statistical analysis of ECG data*

The primary endpoint was defined as the largest time-matched placebo-corrected, mean change-from-baseline QTcF ( $\Delta\Delta\text{QTcF}$ ) in ms of the two gadopiclesol doses. The null hypothesis was that the mean change from baseline in QTcF difference between each of the two doses of gadopiclesol and placebo was greater or equal to the non-inferiority margin for at least one time point. An Intersection-Union test was performed at a one-sided 5% significance level. This is equivalent to compare the upper limit of the two-sided 90% CI of the difference between each of the two doses of gadopiclesol and placebo with the non-inferiority margin of 10 ms at each time point. The primary analysis was performed using an analysis of covariance model for crossover data with baseline data as covariate, sequence, period, trial drug and sex as fixed effect and subject as a random effect. Differences with placebo between means were tested through the model for each time point and for the two doses of gadopiclesol using the Student's t-test. For each time point, the two-sided 90% CI of the difference between each of the two doses of gadopiclesol and placebo were calculated for testing the hypotheses. The primary analysis was conducted on subjects who had no major protocol deviations, defined as having an impact on the primary endpoint (per protocol set). As a supportive analysis, the primary analysis was repeated including all randomized subjects who received at least one study product (safety set).

Assay sensitivity assessment was defined as the largest time-matched placebo-corrected, change from-baseline mean effect of moxifloxacin on QTcF. In order to validate the assay sensitivity of the trial, the positive control had to increase the  $\Delta\Delta\text{QTcF}$  by at least 5 ms for at least one time point. To account for multiple time points, the overall Type I error rate was adjusted according to Hochberg and Tamhane [17].

Considering an expected intra-variability for  $\Delta\text{QTcF}$  of 9 ms and an expected difference of 2 ms between gadopiclesol and placebo, a sample size of 40 subjects was

sufficient to demonstrate non-inferiority with a non-inferiority margin of 10 ms, a power of 85% and a one-sided Type I error of 5%. This sample size was also sufficient to detect a difference of 5 ms (with an expected difference of 12 ms for at least one time point and an expected intra-variability for  $\Delta$ QTcF of 9 ms) between moxifloxacin and placebo with a power of 85%. To account for potential dropouts and/or unevaluable data points, 48 subjects were included in the study.

Categorical analyses were performed to determine the number of subjects for each treatment who had values for QTcF >450 ms, >480 ms and >500 ms and/or changes from baseline in QTcF >30 ms and >60 ms.

### *Plasma Gadopiclenol Concentrations*

Blood samples for the measurement of gadopiclenol concentration were drawn from predose to 24 h postdose in each period except in the period in which moxifloxacin was administered. The time points of blood samplings coincided with those at which ECGs were extracted from the Holter recording.

The concentrations of gadopiclenol in plasma were determined using liquid chromatography methods with tandem mass spectrometry detection. The analytical methods were validated as per FDA and EMA guidance documents [18, 19]. The assays were linear in the concentration range 5–2500  $\mu\text{g}\cdot\text{ml}^{-1}$  and the limit of quantification was 5.0  $\mu\text{g}\cdot\text{ml}^{-1}$ . The performance of the method was monitored using quality control samples at concentrations of 15, 1250 and 2000  $\mu\text{g}\cdot\text{ml}^{-1}$ . At these concentrations, precision (%CV) was  $\leq 4.28\%$  whereas bias varied from 1.44 to 2.59% in plasma.

The plasma concentration data of gadopiclenol were subjected to descriptive statistics and were graphically displayed. No pharmacokinetic analysis was performed.

### *Concentration-response analysis*

A concentration-response relationship was investigated between  $\Delta\Delta\text{QTcF}$  and gadopichlenol concentrations using a mixed linear model with baseline-corrected QTcF as the dependent variable [20]. Placebo data were included in the analysis with concentration values set to 0 and gadopichlenol concentrations below the limit of quantification were also set to 0. The fixed effect parameters of the pre-specified model were intercept, slope for gadopichlenol concentrations, influence of baseline on intercept, study treatment (gadopichlenol or placebo) specific intercept, and theoretical time points post-administration. Subject specific random effects were added on intercept and slope parameters with an unstructured covariance matrix.

The parameters estimated from the selected model are presented with their standard error and 95% confidence interval (CI). The predicted placebo- and baseline-corrected QTcF for each dose level is presented with its 2-sided 90% CI and the model is graphically presented by a regression line over the concentration range collected during the study together with its 90% confidence region. The appropriateness of the chosen linear model was checked by inspecting the standard goodness-of-fit plots.

### *Safety assessments*

The safety and tolerability of gadopichlenol, as compared to baseline and placebo, was assessed by recording of adverse events (AEs), vital signs (blood pressure and pulse rate) measurements, ECG recording, clinical laboratory assessments and monitoring of injection site tolerance. Adverse events were recorded throughout the study, vital signs were recorded at screening and predose up to 24 hours postdose at the same time points as Holter ECGs, 12-lead safety ECGs were done in triplicate within 1 hour before each study treatment administration and 10 min and 3 h post administration and blood samples for clinical laboratory assessments were drawn at screening and on Day 1 and 2 of each treatment period.

Injection-site tolerance (burning, pain, eruption, extravasation, inflammation, or other) was assessed over 1 day following each injection (during the injection, up to 30 min  $\pm$  5 min and the day after injection) and over a longer period if the investigator became aware of any related adverse event. In case of injection-site pain, the subject was asked to specify the level of pain using a visual analogic scale.

## **Results**

### *Subject disposition and demographics*

In this study, 48 subjects were randomised, all received the 4 study treatments and completed the study. Due to the occurrence of extravasation during the injection of placebo, one subject was excluded from the per protocol set. Therefore, 48 and 47 subjects were included in the safety and per protocol sets, respectively.

Half of the enrolled subjects were male and half female and except one Asian subject all were Caucasian. A summary of the demographics of the safety set is provided in Table 1.

### *Effect of gadopichlenol on QTcF and HR, assay sensitivity and categorical analysis*

Baseline QTc of each study period was not significantly different and there was no period effect. Baseline-corrected least-square mean differences between gadopichlenol and placebo and between moxifloxacin and placebo versus time after administration are shown in Figure 1. Following i.v. injection of 0.1 mmol·kg<sup>-1</sup> of gadopichlenol, at none of the tested time points the upper limit of the 90% CI of  $\Delta\Delta\text{QTcF}$  exceeded 10 ms indicating the absence of an effect of gadopichlenol on QTcF. The largest time-matched placebo-corrected change from baseline was recorded 3 h postdose and was 2.39 ms (90% CI: 0.35, 4.43). A similar result was obtained with the supra-clinical dose of 0.3 mmol·kg<sup>-1</sup> with a maximum observed  $\Delta\Delta\text{QTcF}$  of

4.81 ms (90% CI: 2.84, 6.78) occurring at 5 min after i.v. injection. This increase in  $\Delta\Delta\text{QTcF}$  was short-lasting and had disappeared 20 min after administration ( $\Delta\Delta\text{QTcF} = 0.20$  ms (90% CI: -1.71, 2.12)).

Figure 1 also shows a plot of  $\Delta\Delta\text{QTcF}$  versus time following administration of 400 mg moxifloxacin. A relevant (90% CI lower limit > regulatory threshold of 5 ms) increase in  $\Delta\Delta\text{QTcF}$  was first observed 1.5 h after moxifloxacin administration and lasted up to 4 h after administration, with a maximum of 10.83 ms (90% CI: 8.21; 13.46) 4 h post administration. This result demonstrates adequate assay sensitivity of the study.

In this study, no QTcF values exceeding 450 ms and no increases from baseline > 30 ms were recorded. No effect on heart rate was observed for any of the study treatments. The mean maximal placebo-corrected changes from baseline for gadopichlenol- and moxifloxacin-treated subjects were 1.63 bpm (90% CI: -0.14, 3.41) for the 0.1 mmol·kg<sup>-1</sup> group, 2.55 bpm (90% CI: 0.77, 4.34) for the 0.3 mmol·kg<sup>-1</sup> group and 1.71 bpm (90% CI: 0.43, 2.98) in the moxifloxacin group. There was also no significant change in systolic or diastolic blood pressure.

### *Plasma gadopichlenol concentrations*

Following i.v. administration gadopichlenol, concentrations rapidly declined (Figure 2) and at time point 24h all gadopichlenol concentrations were below the limit of quantification. At 1 and 3 months after last study drug administration, the gadopichlenol plasma concentrations were below the limit of quantification in all subjects.

### *Concentration-response analysis*

The concentration-response analysis indicated that there was a relationship between  $\Delta\Delta\text{QTcF}$  and gadopichlenol plasma concentration in that with increasing concentration there was an

increase in  $\Delta\text{QTcF}$ . The final model parameters are summarized in Table 2. A graphical illustration of the model-predicted linear relationship between gadopichlenol concentration and  $\Delta\Delta\text{QTcF}$  is provided in Figure 3. At the geometric mean  $C_{\text{max}}$  of gadopichlenol, the model-predicted effect on  $\Delta\Delta\text{QTcF}$  was 0.41 ms (90% CI: -0.08, 0.90) at a dose of 0.1 mmol·kg<sup>-1</sup> and 2.23 ms (90% CI: 1.19, 3.26) at the supra-clinical dose of 0.3 mmol·kg<sup>-1</sup>.

### *Safety and tolerability*

There were no serious AEs, AEs of severe intensity or AEs that led to premature study withdrawals. A total of 116 treatment emergent AEs were reported in 41 subjects (85.4%): 25 subjects (52.1%) with gadopichlenol 0.1 mmol·kg<sup>-1</sup>, 22 subjects (45.8%) with gadopichlenol 0.3 mmol·kg<sup>-1</sup>, 16 subjects (33.3%) with moxifloxacin and 22 subjects (45.8%) with placebo. A summary of all AEs including those considered not related to study treatments is provided in Table 3. Most AEs (108) were of mild intensity and 8 were moderate (1 with gadopichlenol 0.1 mmol·kg<sup>-1</sup>, 3 with gadopichlenol 0.3 mmol·kg<sup>-1</sup>, 2 with positive control and 2 with placebo).

Overall, fewer AEs were reported by fewer subjects following moxifloxacin administration when compared to i.v. administration of study treatments including placebo. There was no obvious difference in AE reporting between gadopichlenol and placebo.

No safety concern was observed regarding hematology and biochemistry parameters, vital signs remained stable during the study and no clinically significant findings on safety ECG and Holter ECG were observed.

## Discussion

The results of this thorough QT/QTc study show that administration of gadopiclesol, a new macrocyclic GBCA, at standard clinical and supra-clinical doses did not result in a prolongation of the QTc interval in healthy volunteers. At all time points, the upper bound of the 90% CI of  $\Delta\Delta\text{QTcF}$  was less than 10 ms and, therefore, from a regulatory and clinical relevance standpoint this study can be considered negative. The observed increase in QTcF following oral moxifloxacin administration demonstrated that the present study had adequate sensitivity to detect an increase in QTcF.

There are only a limited number of studies published on the effects of GBCAs on the QTc interval. Only one thorough QT/QTc study was reported with gadobutrol which showed an  $\Delta\Delta\text{QTc}$  increase of 9.91 ms (90% CI 8.01–11.81) at a dose of 0.5 mmol·kg<sup>-1</sup>. This marginally positive QT-prolonging effect decreased to 7.62 ms (90% CI: 6.37, 8.87), i.e., a negative thorough QT study, after QT/RR hysteresis correction [21], Hysteresis correction was justified by a 13.1 bpm increase in heart rate which did not occur in our study. A randomized, double-blind, placebo-controlled, crossover clinical trial in patients requiring contrast-enhanced magnetic resonance imaging did not show any significant QTc prolongation with gadoterate meglumine [22]. In a 2-way crossover study comparing gadobenate at a dose of 0.2 mmol·kg<sup>-1</sup> to placebo an increase of 3.1 ms in  $\Delta\Delta\text{QTcB}$  was observed with no difference between healthy volunteers and patients with coronary artery disease [23]. It is interesting to note that both gadobutrol and gadobenate have a higher osmolarity at marketed concentrations (1603 and 1970 mOsm·l<sup>-1</sup>, respectively) than gadopiclesol (843 mOsm·l<sup>-1</sup>) [13]. In a comparative study of the high-osmolarity iodinated contrast agent diatrizoate (osmolarity: 1515 mOsm·l<sup>-1</sup> [24]) and the low-osmolarity iodinated contrast agents ioxaglate, iopamidol and iohexol, diatrizoate had the largest effect on QTc [25]. It is thus likely that the small effects on QTc observed in this and other studies with

GBCAs are related to the high osmolarity of the compounds rather than to their chemical structure and this is supported by *in vitro* data [11, 22]. The concentration-response analysis confirmed the absence of clinically significant QTc prolongation with gadopichlenol. However, since there was a positive relationship between gadopichlenol concentration and QTc response, it cannot be excluded that contrast agents of greater osmolarity could be associated with clinically significant QTc prolongation.

Another hypothesis to explain small and transient QTc prolongation with hyperosmolar compounds could be linked to abrupt changes in ventricular loading associated with increased blood pressure [26, 27]. However, such an effect was not documented in this and other studies of GBCAs and there was no significant change in blood pressure in the present study.

The pharmacokinetic and safety profile observed in the present study are in line with previously published results [13] and confirm the good safety profile of gadopichlenol. AEs were mainly related to the mode of administration and their frequency did not differ from placebo.

A limitation of the present study is that it was performed in healthy volunteers who did not have electrolyte abnormalities that could possibly affect cardiac conduction, with ECGs devoid of any clinically relevant abnormality and who were not treated with concomitant medications that could possibly affect cardiac repolarisation. Patients who are scheduled to undergo an MRI may have any of the above.

In conclusion, results from this thorough QT/QTc study show that both anticipated clinical and supra-clinical doses i.v. gadopichlenol do not prolong the QTc interval and confirm the previously observed favourable safety and pharmacokinetic profiles. In addition, the study supports the view that hyperosmolarity of gadolinium-based contrast agent could be associated with minimal and clinically insignificant prolongation of ventricular repolarization.



## **Authors contribution**

All authors were involved in the study design, data interpretation, reviewed the results and approved the final manuscript.

N.L.F., C.D., and P.D. supervised the study conduct

F.V. was responsible for the study conduct

P.V. supervised the central reading of the ECGs

M.F. supervised the statistical analyses

C.F-B. produced the final version of the manuscript

## **Competing interests**

CF-B, PV, FV, and MF had support from Guerbet for the submitted work. NLF, CD and PD are current employees of Guerbet. There are no other relationships or activities that could appear to have influenced the submitted work.

*This study was funded by Guerbet. Medical writing support was provided by Paul van Giersbergen, (Van Giersbergen Consulting, Wuenheim, France) and was funded by Guerbet.*

## **Data availability statement:**

Data will be available on request from the authors after product registration (product under development)

## References

1. Morana G, Cugini C, Scatto G, Zanato R, Fusaro M, Dorigo A. Use of contrast agents in oncological imaging: magnetic resonance imaging. *Cancer Imaging*. 2013;13:350-9.
2. Zhou Z, Lu ZR. Gadolinium-based contrast agents for magnetic resonance cancer imaging. *Wiley Interdiscip Rev Nanomed Nanobiotechnol*. 2013;5:1-18.
3. Bellin MF, Van Der Molen AJ. Extracellular gadolinium-based contrast media: an overview. *Eur J Radiol*. 2008;66:160-7.
4. Kanal E, Maravilla K, Rowley HA. Gadolinium contrast agents for CNS imaging: current concepts and clinical evidence. *AJNR Am J Neuroradiol*. 2014;35:2215-26.
5. Grobner T. Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? *Nephrol Dial Transplant*. 2006;21:1104-8.
6. Grobner T, Prischl FC. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure. *Semin Dial*. 2008;21:135-9.
7. Ramalho J, Semelka RC, Ramalho M, Nunes RH, AlObaidy M, Castillo M. Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update. *AJNR Am J Neuroradiol*. 2016;37:1192-8.
8. Fraum TJ, Ludwig DR, Bashir MR, Fowler KJ. Gadolinium-based contrast agents: A comprehensive risk assessment. *J Magn Reson Imaging*. 2017;46:338-53.
9. Rogosnitzky M, Branch S. Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms. *Biometals*. 2016;29:365-76.

10. Lancelot E, Desche P. Gadolinium Retention as a Safety Signal: Experience of a Manufacturer. *Invest Radiol.* 2020;55:20-24.
11. Yabuuchi F, Beckmann R, Wettwer E, Hegele-Hartung C, Heubach JF. Reduction of hERG potassium currents by hyperosmolar solutions. *Eur J Pharmacol.* 2007;566:222-5.
12. Jacobsen EA, Pedersen HK, Klow NE, Refsum H. Cardiac electrophysiology, arrhythmogenic mechanisms and roentgen contrast media. *Acta Radiol Suppl.* 1995;399:105-14.
13. Hao J, Bourrinet P, Desche P. Assessment of Pharmacokinetic, Pharmacodynamic Profile, and Tolerance of Gadopiclenol, A New High Relaxivity GBCA, in Healthy Subjects and Patients With Brain Lesions (Phase I/IIa Study). *Invest Radiol.* 2019;54:396-402.
14. Bendszus M, Roberts D, Kolumban B, Meza J, Berezki D, San-Juan D, et al. Dose finding study of Gadopiclenol, a new macrocyclic contrast agent, in MRI of central nervous system. *Invest Radiol.* 2020 (*In Press*);
15. International Conference on Harmonization. E14: Clinical evaluation of QT. 2005. available at <https://www.ich.org/page/efficacy-guidelines>; (last accessed: 21 December 2019).
16. Williams E. Experimental designs balanced for the estimation of residual effects of treatments. *Aust J Sci Res B.* 1949;2:149-68.
17. Hochberg Y, Tamhane A. Multiple comparison procedures. John Wiley & Sons, New York, NY, USA, 1987.
18. Food and Drug Administration. Bioanalytical Method Validation Guidance for Industry 2018. Available at <https://www.fda.gov/regulatory-information/search-fda-guidance->

- [documents/bioanalytical-method-validation-guidance-industry](#); (last accessed: 21 December 2019).
19. European Medicine Agency. Bioanalytical method validation. 2011. Available at <https://www.ema.europa.eu/en/bioanalytical-method-validation>; (last accessed: 21 December 2019).
  20. Garnett C, Bonate PL, Dang Q, Ferber G, Huang D, Liu J, et al. Scientific white paper on concentration-QTc modeling. *J Pharmacokinet Pharmacodyn*. 2018;45:383-97.
  21. Malik M, Hnatkova K, Schmidt A, Smetana P. Correction for QT/RR hysteresis in the assessment of drug-induced QTc changes--cardiac safety of gadobutrol. *Ann Noninvasive Electrocardiol*. 2009;14:242-50.
  22. Bourrinet P, Martel E, El Amrani AI, Champeroux P, Richard S, Fauchou N, et al. Cardiovascular safety of gadoterate meglumine (Gd-DOTA). *Invest Radiol*. 2007;42:63-77.
  23. Pirovano G, Goodman DB, Halemane U, Venetianer C, Kirchin MA, Spinazzi A. Cardiac electrophysiologic monitoring after injection of gadobenate dimeglumine versus placebo in healthy volunteers and patients with cardiovascular disease. *Radiology*. 2004;233:555-65.
  24. Drug label information (Dailymed). Hypaque sodium - Diatrizoate Sodium injection, solution. Available at <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02ff6501-cccc-4f7d-9988-856d4e169b0e>; (last accessed: 21 December 2019).

25. Mitsumori M, Hayakawa K, Soga T, Maeda M, Torizuka T, Okuno Y, et al. Effects of contrast media on the RR and QT interval during coronary arteriography. *Acta Radiol.* 1991;32:120-3.
26. Taggart P, Sutton P, Lab M, Runnalls M, O'Brien W, Treasure T. Effect of abrupt changes in ventricular loading on repolarization induced by transient aortic occlusion in humans. *Am J Physiol.* 1992;263:H816-23.
27. Taggart P, Sutton P, John R, Lab M, Swanton H. Monophasic action potential recordings during acute changes in ventricular loading induced by the Valsalva manoeuvre. *Br Heart J.* 1992;67:221-9.

**Table 1**

Summary of demographic characteristics

|                                      |           | <b>All subjects</b> |
|--------------------------------------|-----------|---------------------|
| Age (years)                          | Mean (SD) | 40.5 (11.6)         |
|                                      | Range     | 19–59               |
| Males / Females (n)                  |           | 24 / 24             |
| Race ( <i>n</i> , %)                 | Asian     | 1 (2.1%)            |
|                                      | Caucasian | 47 (97.9%)          |
| Weight (kg)                          | Mean (SD) | 75.3 (8.5)          |
|                                      | Range     | 58–97               |
| Height (cm)                          | Mean (SD) | 173.5 (8.5)         |
|                                      | Range     | 154–190             |
| Body mass index (kg/m <sup>2</sup> ) | Mean (SD) | 25.0 (2.2)          |
|                                      | Range     | 19.8–28.2           |

**Table 2**

Model parameters of final concentration-response model

|  | <b>Parameter estimate (SE)</b> | <b>95% CI</b>   |
|--|--------------------------------|-----------------|
| Intercept (placebo) (ms)                           | -2.88 (1.07)                   | -5.04 – -0.72   |
| Slope (ms per $\mu\text{g} \cdot \text{ml}^{-1}$ ) | 0.0011 (0.0003)                | 0.0005 – 0.0016 |
| Baseline covariate (ms)                            | -0.40 (0.03)                   | -0.47 – -0.33   |
| Gadopiclenol specific intercept (ms)               | -0.40 (0.35)                   | -1.09 – 0.30    |

**Table 3**

Summary of treatment-emergent AEs that occurred in at least 2 subjects

|                              | Gadopichlenol                    |     | Gadopichlenol                    |     | Moxifloxacin  |     | Placebo    |     |
|------------------------------|----------------------------------|-----|----------------------------------|-----|---------------|-----|------------|-----|
|                              | 0.1 mmol·kg <sup>-1</sup> (N=48) |     | 0.3 mmol·kg <sup>-1</sup> (N=48) |     | 400 mg (N=48) |     | (N=48)     |     |
|                              | Subjects                         | AEs | Subjects                         | AEs | Subjects      | AEs | Subjects   | AEs |
| At least one AE              | 25 (52.1%)                       | 33  | 22 (45.8%)                       | 33  | 16 (33.3%)    | 18  | 22 (45.8%) | 32  |
| Application site irritation* | 6 (12.5%)                        | 7   | 7 (14.6%)                        | 8   | 5 (10.4%)     | 5   | 6 (12.5%)  | 6   |
| Headache                     | 6 (12.5%)                        | 6   | 5 (10.4%)                        | 6   | 4 (8.3%)      | 4   | 4 (8.3%)   | 4   |
| Injection site haematoma     | 4 (8.3%)                         | 4   | 3 (6.3%)                         | 3   | 0 (0.0%)      | 0   | 1 (2.1%)   | 1   |
| Injection site pain          | 2 (4.2%)                         | 2   | 0 (0.0%)                         | 0   | 0 (0.0%)      | 0   | 4 (8.3%)   | 4   |
| Diarrhoea                    | 0 (0.0%)                         | 0   | 1 (2.1%)                         | 1   | 3 (6.3%)      | 3   | 2 (4.2%)   | 2   |
| Injection site erythema      | 2 (4.2%)                         | 2   | 1 (2.1%)                         | 1   | 0 (0.0%)      | 0   | 1 (2.1%)   | 1   |
| Dysgeusia                    | 1 (2.1%)                         | 1   | 1 (2.1%)                         | 1   | 0 (0.0%)      | 0   | 2 (4.2%)   | 2   |
| Dizziness                    | 1 (2.1%)                         | 1   | 0 (0.0%)                         | 0   | 2 (4.2%)      | 2   | 0 (0.0%)   | 0   |
| Nausea                       | 0 (0.0%)                         | 0   | 2 (4.2%)                         | 2   | 0 (0.0%)      | 0   | 1 (2.1%)   | 1   |




|                             |          |   |          |   |          |   |          |   |
|-----------------------------|----------|---|----------|---|----------|---|----------|---|
| Abdominal pain              | 1 (2.1%) | 1 | 0 (0.0%) | 0 | 0 (0.0%) | 0 | 1 (2.1%) | 1 |
| Injection site reaction*    | 1 (2.1%) | 1 | 0 (0.0%) | 0 | 1 (2.1%) | 1 | 0 (0.0%) | 0 |
| Catheter site haematoma     | 1 (2.1%) | 1 | 1 (2.1%) | 1 | 0 (0.0%) | 0 | 0 (0.0%) | 0 |
| Injection site inflammation | 1 (2.1%) | 1 | 0 (0.0%) | 0 | 0 (0.0%) | 0 | 1 (2.1%) | 1 |
| Injection site rash         | 1 (2.1%) | 1 | 1 (2.1%) | 1 | 0 (0.0%) | 0 | 0 (0.0%) | 0 |
| Oropharyngeal pain          | 0 (0.0%) | 0 | 1 (2.1%) | 1 | 0 (0.0%) | 0 | 1 (2.1%) | 1 |
| Back pain                   | 0 (0.0%) | 0 | 2 (4.2%) | 2 | 0 (0.0%) | 0 | 0 (0.0%) | 0 |

---


\* These adverse events were associated with catheter placement or the electrode patches

## Figure legends




**Figure 1**

Time-matched, placebo-corrected change from baseline in QTcF ( $\Delta\Delta\text{QTcF}$ ). Data are presented as time-matched least square differences between study drugs and placebo and their corresponding 90% CI.  $\blacktriangle$ – $\blacktriangle$ , 0.1 mmol·kg<sup>-1</sup> i.v. gadopidlenol,  $\blacksquare$ – $\blacksquare$ , 0.3 mmol·kg<sup>-1</sup> i.v. gadopidlenol,  $\bullet$ – $\bullet$ , 400 mg oral moxifloxacin. The threshold of 10 ms is shown as a dotted horizontal line.



**Figure 2**

Plasma concentration-time profiles of gadopicolenol. Data are presented as arithmetic mean  $\pm$  SD.  $\blacktriangle$ – $\blacktriangle$ , 0.1  $\text{mmol}\cdot\text{kg}^{-1}$  i.v. gadopicolenol,  $\blacksquare$ – $\blacksquare$ , 0.3  $\text{mmol}\cdot\text{kg}^{-1}$  i.v. gadopicolenol.



**Figure 3**

Model-predicted effect of gadopichlenol on baseline- and placebo-corrected QTcF ( $\Delta\Delta\text{QTcF}$ ) over a concentration range of 0 to 4000  $\mu\text{g} \cdot \text{ml}^{-1}$ . The  $\Delta\Delta\text{QTcF}$  at the doses of 0.1  $\text{mmol} \cdot \text{kg}^{-1}$  ( $\blacktriangle$ ) and 0.3  $\text{mmol} \cdot \text{kg}^{-1}$  ( $\blacksquare$ ) are shown with their respective 90% CI. The lines represent the model-predicted linear relationship between concentration and effect on  $\Delta\Delta\text{QTcF}$  and the lower and upper 90% CI.